Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer

BET inhibitors are promising therapeutic agents for the treatment of triple-negative breast cancer (TNBC), but the rapid emergence of resistance necessitates investigation of combination therapies and their effects on tumor evolution. Here, we show that palbociclib, a CDK4/6 inhibitor, and paclitaxe...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Nat Commun
Autori principali: Ge, Jennifer Y., Shu, Shaokun, Kwon, Mijung, Jovanović, Bojana, Murphy, Katherine, Gulvady, Anushree, Fassl, Anne, Trinh, Anne, Kuang, Yanan, Heavey, Grace A., Luoma, Adrienne, Paweletz, Cloud, Thorner, Aaron R., Wucherpfennig, Kai W., Qi, Jun, Brown, Myles, Sicinski, Piotr, McDonald, Thomas O., Pellman, David, Michor, Franziska, Polyak, Kornelia
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Publishing Group UK 2020
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7214447/
https://ncbi.nlm.nih.gov/pubmed/32393766
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-020-16170-3
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi